MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials
Authors:
- Francesco RussanoFRFrancesco Russano
- Mattia SturleseMattia Sturlese
- Luigi Dall’olmoLDLuigi Dall’olmo
- Francesco CallegarinFCFrancesco Callegarin
- Davide BrugnoloDBDavide Brugnolo
- Paolo Del FiorePFPaolo Del Fiore
- Vittoria PattiVPVittoria Patti
- Arianna PurpuraAPArianna Purpura
- Stefano MoroStefano Moro
- Marco RastrelliMRMarco Rastrelli
- Simone MocellinSimone Mocellin
Open Access
- 22 December 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 99
Abstract
The Murine Double Minute 2 (MDM2) gene encodes an E3 ubiquitin ligase that negatively regulates the tumor suppressor p53, maintaining low p53 levels through ubiquitination and proteasomal degradation. MDM2 overexpression in various malignancies leads to reduced p53 activity, contributing to tumor initiation and resistance to therapies. As such, MDM2 is a promising target for drug development. Innovative small-molecule inhibitors are being designed to disrupt the MDM2-p53 interaction, thereby restoring p53’s tumor-suppressive functions. This review focuses on clinical trials evaluating MDM2 inhibition for cancer therapy. MDM2 exerts its oncogenic effects primarily through its interaction with p53 but also has p53-independent functions involved in cell cycle progression and DNA repair. Elevated MDM2 expression is associated with poor prognosis across various cancers, including dedifferentiated liposarcoma, breast cancer, and glioblastoma. Targeting MDM2 with inhibitors has shown promising potential in clinical development, aiming to reactivate p53’s functions in tumors with wild-type TP53, improving therapeutic outcomes in cancer treatment.Keywords
All Related Versions
Funding Information
- Italian Ministry of Health to cover publication costs
This publication has 51 references indexed in Scilit:
- A critical review of the synergistic potential of targeting p53 and CAR T cell therapy in cancer treatmentBiomedicine & Pharmacotherapy, 2025
- Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancerCritical Reviews in Oncology/Hematology, 2025
- MDM2 inhibitors in cancer immunotherapy: Current status and perspectiveGenes & Diseases, 2024
- A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumorsESMO Open, 2024
- Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimensSaudi Pharmaceutical Journal, 2023
- Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical DevelopmentJournal of Medicinal Chemistry, 2023
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?Journal of Medicinal Chemistry, 2017
- Synergistic cooperation of MDM2 and E2F1 contributes to TAp73 transcriptional activityBiochemical and Biophysical Research Communications, 2014
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyThe Lancet Oncology, 2012
- The E2F1/Rb and p53/MDM2 Pathways in DNA Repair and Apoptosis: Understanding the Crosstalk to Develop Novel Strategies for Prostate Cancer RadiotherapySeminars in Radiation Oncology, 2010